Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
Thymic carcinomas are particularly more concerning due to their aggressive metastatic nature
and shorter overall survival, in comparison to their lesser-malignant thymoma counterparts.
This necessitates the need for systemic therapy. Due to the paucity of thymic carcinoma
cases, the ideal regimen for locally advanced or metastatic thymic carcinomas is not
defined.To this point, there has not been a study using imatinib in thymic tumors expressing
the KIT tyrosine kinase protein or PDGF tyrosine kinase protein. This study is important to
demonstrate if single agent activity is noted for patients with thymic tumors over
expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to
evaluate other combination of drugs with imatinib in thymic tumors.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the objective response rate of imatinib in patients with c-kit or PDGF positive thymic carcinoma.
baseline through progression
United States: Food and Drug Administration
|Indiana University Cancer Center||Indianapolis, Indiana 46202-5265|